Application | Comment | Organism |
---|---|---|
pharmacology | detailed pharmacodynamic analysis of aliskiren in humans. Development of an integrated pharmacokinetik/pharmacodynamic model for aliskiren, including an empirical submodel to account for additional complexities arising from multiple dosing | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
aliskiren | aliskiren produces a parallel, dose-related, sustained decrease in plasma renin activity, angiotensin I, and angiotensin II levels and a slightly delayed increase in active renin. The effect is described by an indirect stimulatory response model in conjunction with an empirical submodel of functional adaptation. Estimated concentration of aliskiren necessary for producing 50% inhibition of plasma renin activity is 0.66 ng/ml | Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
additional information | - |
aliskiren | estimated Km1 value is 0.516 ng/ml, Km2 value is 135 ng/ml | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
aliskiren + H2O | - |
Homo sapiens | ? | - |
? |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
additional information | - |
estimated concentration of aliskiren necessary for producing 50% inhibition of plasma renin activity is 0.66 ng/ml | Homo sapiens | aliskiren |